Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Depression

Sertraline may reduce anxiety more quickly than depressive symptoms

Researchers found that sertraline was unlikely to reduce depressive symptoms within six weeks but secondary analyses showed that it reduced anxiety symptoms

Sertraline blister pack

Source: Stuart Donaldson / Alamy Stock Photo

Secondary analyses showed that sertraline led to reduced anxiety symptoms, better mental health-related quality of life and self-reported improvements in mental health

Sertraline is unlikely to reduce depressive symptoms within six weeks, compared with placebo, according to findings from a randomised controlled trial published in The Lancet Psychiatry (19 September 2019)[1].

However, secondary analyses showed that sertraline led to reduced anxiety symptoms and better mental health-related quality of life.

Researchers from University College London (UCL) examined the effects of sertraline among 653 primary care patients with depressive symptoms where there was clinical uncertainty about the benefit of an antidepressant.

They found that sertraline was unlikely to reduce depressive symptoms within six weeks, compared with placebo, and there was only weak evidence that it reduced depressive symptoms at 12 weeks. 

But, participants in the sertraline group were found to be twice as likely as those in the placebo group to say their mental health had improved overall (adjusted odds ratio 1.96, 95% confidence interval 1.45—2.63; P<0.0001).

The authors concluded that antidepressants could benefit a wider group of people than previously believed, including people who do not meet diagnostic criteria for depression or generalised anxiety disorder.

“Sertraline is effective for the people likely to receive antidepressants in primary care,” said study author Glyn Lewis, head of division at UCL Psychiatry.

“They work, just in a different way than we had expected.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207235

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.